img

Post-pandemic Era Global Age-related Macular Degeneration Market Segment Research Report 2024

Published on: 2024-01-04 | No of Pages : 212 | Industry : Medical Devices & Consumables Research Center

Publisher : XMR | Format : PDF

Post-pandemic Era Global Age-related Macular Degeneration Market Segment Research Report 2024

Summary

The global economy is expected to expand 5.6% in 2021，global recovery is strong but uneven as many emerging market and developing economies continue to struggle with the COVID-19 pandemic, the world is unlikely to ever reach global herd immunity. However, the recovery in many countries is being held back by a resurgence of COVID-19 cases and lagging vaccination progress, as well as the withdrawal of policy support in some instances.

The annual U.S. economic growth rate slipped to -3.5% in 2020, but grew at a yearly pace of more than 6% in the previous two quarters of 2021. The economy of continental Europe bounced back in the second quarter after having contracted in both the fourth quarter of 2020 and the first quarter of 2021, as the vaccinations accelerated, and governments eased restrictions. Among major economies, the annualized growth rate was 6.1% in Germany, 3.6% in France, 11.2% in Italy, and 11.7% in Spain. The especially rapid growth in Spain and Italy was attributed to a surge in consumer spending, likely the result of an easing of economic restrictions.

Regional Economic ProspectsGrowth in the East Asia and Pacific is projected to accelerate by 7.7% in 2021, Central Asia is forecast to grow by 3.9% this year, economic activity in the Middle East and North Africa is forecast to advance by 2.4%, South Asia is projected to expand by 6.8%.

The global Age-related Macular Degeneration market size was USD XX billion in 2021. It is likely to progress at a CAGR of XX% during the forecast period of 2022-2027, according to MR Accuracy Reports analysis, The segment in Age-related Macular Degeneration market is estimated to reach a market value of USD XX billion by 2021 from an initial market value of USD XX billion in 2021. China market value in 2021 is about USD XX billion, and China Age-related Macular Degeneration production is XX (K Units). US market value in 2021 is about USD XX billion, and US Age-related Macular Degeneration production is XX (K Units). Europe market value in 2021 is about USD XX billion, and Europe Age-related Macular Degeneration production is XX (K Units).

Regional Segmentation (Value; Revenue, USD Million, 2017 - 2027) of Age-related Macular Degeneration Market by MR Accuracy Reports Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Age-related Macular Degeneration Market?
Bayer HealthCare
F. Hoffmann-La Roche
Novartis
Regeneron Pharmaceuticals
Alcon
Allergan
Avalanche
Bausch+Lomb
Gilead Sciences
Iconic Therapeutics
Neurotech Pharmaceuticals
Ohr Pharmaceutical
Major Type of Age-related Macular Degeneration Covered in MR Accuracy Reports report
Wet AMD
Dry AMD
Application Segments Covered in MR Accuracy Reports Market
Drugstore
Hospital
Others

For any other requirements, please feel free to contact us and we will provide you customized report.

Table of Content

Table of Contents

Global Age-related Macular Degeneration Market Segment Research Report 2021
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Age-related Macular Degeneration Market by Value
2.2.1 Global Age-related Macular Degeneration Revenue by Type
2.2.2 Global Age-related Macular Degeneration Market by Value (%)
2.3 Global Age-related Macular Degeneration Market by Production
2.3.1 Global Age-related Macular Degeneration Production by Type
2.3.2 Global Age-related Macular Degeneration Market by Production (%)

3. The Major Driver of Age-related Macular Degeneration Industry
3.1 Historical & Forecast Global Age-related Macular Degeneration Demand
3.2 Largest Application for Age-related Macular Degeneration (2017-2027)
3.3 The Major Downstream Company in China Market 2021

4. Global and Regional Age-related Macular Degeneration Market
4.1 Regional Market Size in Terms of Production & Demand (2021)
4.2 Regional Market Share in Terms of Revenue (2019-2027)
4.3 Concentration Ratio (CR5& CR10) of Age-related Macular Degeneration Market
4.4 Mergers & Acquisitions, Expansion Plans

5. US Age-related Macular Degeneration Production, Demand (2017-2027)
5.1 Current and Estimated Production Breakdown by Type
5.2 Current and Estimated Demand Breakdown by Type
5.3 Current and Estimated Demand Breakdown by Application
5.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
5.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

6. Europe Age-related Macular Degeneration Production, Demand (2017-2027)
6.1 Current and Estimated Production Breakdown by Type
6.2 Current and Estimated Demand Breakdown by Type
6.3 Current and Estimated Demand Breakdown by Application
6.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
6.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

7. China Age-related Macular Degeneration Production, Demand (2017-2027)
7.1 Current and Estimated Production Breakdown by Type
7.2 Current and Estimated Demand Breakdown by Type
7.3 Current and Estimated Demand Breakdown by Application
7.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
7.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

8. Japan Age-related Macular Degeneration Production, Demand (2017-2027)
8.1 Current and Estimated Production Breakdown by Type
8.2 Current and Estimated Demand Breakdown by Type
8.3 Current and Estimated Demand Breakdown by Application
8.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
8.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

9. India Age-related Macular Degeneration Production, Demand (2017-2027)
9.1 Current and Estimated Production Breakdown by Type
9.2 Current and Estimated Demand Breakdown by Type
9.3 Current and Estimated Demand Breakdown by Application
9.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
9.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

10. Korea Age-related Macular Degeneration Production, Demand (2017-2027)
10.1 Current and Estimated Production Breakdown by Type
10.2 Current and Estimated Demand Breakdown by Type
10.3 Current and Estimated Demand Breakdown by Application
10.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
10.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

11. Southeast Asia Age-related Macular Degeneration Production, Demand (2017-2027)
11.1 Current and Estimated Production Breakdown by Type
11.2 Current and Estimated Demand Breakdown by Type
11.3 Current and Estimated Demand Breakdown by Application
11.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
11.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

12. Global Age-related Macular Degeneration Average Price Trend
12.1 Market Price for Each Type of Age-related Macular Degeneration in US (2017-2021)
12.2 Market Price for Each Type of Age-related Macular Degeneration in Europe (2017-2021)
12.3 Market Price for Each Type of Age-related Macular Degeneration in China (2017-2021)
12.4 Market Price for Each Type of Age-related Macular Degeneration in Japan (2017-2021)
12.5 Market Price for Each Type of Age-related Macular Degeneration in India (2017-2021)
12.6 Market Price for Each Type of Age-related Macular Degeneration in Korea (2017-2021)
12.7 Market Price for Each Type of Age-related Macular Degeneration in Southeast Asia (2017-2021)

13. Industrial Chain (Impact of COVID-19)
13.1 Age-related Macular Degeneration Industrial Chain Analysis
13.2 Downstream
13.3 Impact of COVID-19
13.4 Technology Trends of Age-related Macular Degeneration

14. Age-related Macular Degeneration Competitive Landscape
14.1 Bayer HealthCare
14.1.1 Bayer HealthCare Company Profiles
14.1.2 Bayer HealthCare Product Introduction
14.1.3 Bayer HealthCare Age-related Macular Degeneration Sales, Revenue (2017-2021)
14.1.4 Strategic initiatives
14.2 F. Hoffmann-La Roche
14.2.1 F. Hoffmann-La Roche Company Profiles
14.2.2 F. Hoffmann-La Roche Product Introduction
14.2.3 F. Hoffmann-La Roche Age-related Macular Degeneration Sales, Revenue (2017-2021)
14.2.4 Strategic initiatives
14.3 Novartis
14.3.1 Novartis Company Profiles
14.3.2 Novartis Product Introduction
14.3.3 Novartis Age-related Macular Degeneration Sales, Revenue (2017-2021)
14.3.4 Strategic initiatives
14.4 Regeneron Pharmaceuticals
14.4.1 Regeneron Pharmaceuticals Company Profiles
14.4.2 Regeneron Pharmaceuticals Product Introduction
14.4.3 Regeneron Pharmaceuticals Age-related Macular Degeneration Sales, Revenue (2017-2021)
14.4.4 Strategic initiatives
14.5 Alcon
14.5.1 Alcon Company Profiles
14.5.2 Alcon Product Introduction
14.5.3 Alcon Age-related Macular Degeneration Sales, Revenue (2017-2021)
14.5.4 Strategic initiatives
14.6 Allergan
14.6.1 Allergan Company Profiles
14.6.2 Allergan Product Introduction
14.6.3 Allergan Age-related Macular Degeneration Sales, Revenue (2017-2021)
14.6.4 Strategic initiatives
14.7 Avalanche
14.7.1 Avalanche Company Profiles
14.7.2 Avalanche Product Introduction
14.7.3 Avalanche Age-related Macular Degeneration Sales, Revenue (2017-2021)
14.7.4 Strategic initiatives
14.8 Bausch+Lomb
14.8.1 Bausch+Lomb Company Profiles
14.8.2 Bausch+Lomb Product Introduction
14.8.3 Bausch+Lomb Age-related Macular Degeneration Sales, Revenue (2017-2021)
14.8.4 Strategic initiatives
14.9 Gilead Sciences
14.9.1 Gilead Sciences Company Profiles
14.9.2 Gilead Sciences Product Introduction
14.9.3 Gilead Sciences Age-related Macular Degeneration Sales, Revenue (2017-2021)
14.9.4 Strategic initiatives
14.10 Iconic Therapeutics
14.10.1 Iconic Therapeutics Company Profiles
14.10.2 Iconic Therapeutics Product Introduction
14.10.3 Iconic Therapeutics Age-related Macular Degeneration Sales, Revenue (2017-2021)
14.10.4 Strategic initiatives
14.11 Neurotech Pharmaceuticals
14.12 Ohr Pharmaceutical
15. Conclusion


List of Figure

List of Tables and Figures

Figure 1. Total Demand by Application of Age-related Macular Degeneration Industry (Volume)
Figure 2. Age-related Macular Degeneration Production & Demand by Regions in 2021
Figure 3. Regional Market Share in Terms of Revenue (2021&2027)
Figure 4. The Top 10 and 5 Players Market Share by Age-related Macular Degeneration Revenue in 2021
Figure 5. US Age-related Macular Degeneration Production, Demand (2017-2027)
Figure 6. Production Breakdown by Type (%)
Figure 7. Demand Breakdown by Type (%)
Figure 8. Demand Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Age-related Macular Degeneration Production, Demand (2017-2027)
Figure 12. Production Breakdown by Type (%)
Figure 13. Demand Breakdown by Type (%)
Figure 14. Demand Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Age-related Macular Degeneration Production, Demand (2017-2027)
Figure 18. Production Breakdown by Type (%)
Figure 19. Demand Breakdown by Type (%)
Figure 20. Demand Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Age-related Macular Degeneration Production, Demand (2017-2027)
Figure 25. Production Breakdown by Type (%)
Figure 26. Demand Breakdown by Type (%)
Figure 27. Demand Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Age-related Macular Degeneration Production, Demand (2017-2027)
Figure 31. Production Breakdown by Type (%)
Figure 32. Demand Breakdown by Type (%)
Figure 33. Demand Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Age-related Macular Degeneration Production, Demand (2017-2027)
Figure 37. Production Breakdown by Type (%)
Figure 38. Demand Breakdown by Type (%)
Figure 39. Demand Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Age-related Macular Degeneration Production, Demand (2017-2027)
Figure 43. Current and Estimated Production Breakdown by Type (2017-2027)
Figure 44. Production Breakdown by Type (%)
Figure 45. Demand Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Age-related Macular Degeneration Revenue, by Type (Million USD) (2017-2027)
Table 4. Age-related Macular Degeneration Production, by Type (K Unit) (2017-2027)
Table 5. Age-related Macular Degeneration Demand (K Unit) by Application (2017-2027)
Table 6. Age-related Macular Degeneration Demand (Million USD) by Application (2017-2027)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Production & Demand (2021)
Table 9. Regional Market Share in Terms of Revenue (2021&2027)
Table 10. Ranking of Global Top Age-related Macular Degeneration Companies by Revenue, Concentration Ratio in 2021
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Age-related Macular Degeneration Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 13. Current and Estimated Production Breakdown by Type (2017-2027)
Table 14. Current and Estimated Demand Breakdown by Type (2017-2027)
Table 15. Current and Estimated Demand Breakdown by Application (2017-2027)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Age-related Macular Degeneration Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 19. Current and Estimated Production Breakdown by Type (2017-2027)
Table 20. Current and Estimated Demand Breakdown by Type (2017-2027)
Table 21. Current and Estimated Demand Breakdown by Application (2017-2027)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Age-related Macular Degeneration Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 25. Table Current and Estimated Production Breakdown by Type
Table 26. Current and Estimated Demand Breakdown by Type
Table 27. Current and Estimated Demand Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Age-related Macular Degeneration Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 30. Current and Estimated Production Breakdown by Type (2017-2027)
Table 31. Current and Estimated Demand Breakdown by Type (2017-2027)
Table 32. Current and Estimated Demand Breakdown by Application (2017-2027)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Age-related Macular Degeneration Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 36. Current and Estimated Production Breakdown by Type (2017-2027)
Table 37. Current and Estimated Demand Breakdown by Type (2017-2027)
Table 38. Current and Estimated Demand Breakdown by Application (2017-2027)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Age-related Macular Degeneration Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 42. Current and Estimated Production Breakdown by Type (2017-2027)
Table 43. Current and Estimated Demand Breakdown by Type (2017-2027)
Table 44. Current and Estimated Demand Breakdown by Application (2017-2027)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Age-related Macular Degeneration Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 48. Table Current and Estimated Demand Breakdown by Type (2017-2027)
Table 49. Current and Estimated Demand Breakdown by Application (2017-2027)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Age-related Macular Degeneration in US (2017-2021)
Table 53. Market Price (USD/Unit) for Each Type of Age-related Macular Degeneration in Europe (2017-2021)
Table 54. Market Price (USD/Unit) for Each Type of Age-related Macular Degeneration in China (2017-2021)
Table 55. Market Price (USD/Unit) for Each Type of Age-related Macular Degeneration in Japan (2017-2021)
Table 56. Market Price (USD/Unit) for Each Type of Age-related Macular Degeneration in India (2017-2021)
Table 57. Market Price (USD/Unit) for Each Type of Age-related Macular Degeneration in Korea (2017-2021)
Table 58. Market Price (USD/Unit) for Each Type of Age-related Macular Degeneration in Southeast Asia (2017-2021)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Bayer HealthCare Profiles
Table 61. Bayer HealthCare Age-related Macular Degeneration Product Introduction
Table 62. Bayer HealthCare Age-related Macular Degeneration Sales (Unit), Revenue (Million USD) (2017-2021)
Table 63. Bayer HealthCare Strategic initiatives
Table 64. F. Hoffmann-La Roche Profiles
Table 65. F. Hoffmann-La Roche Age-related Macular Degeneration Product Introduction
Table 66. F. Hoffmann-La Roche Age-related Macular Degeneration Sales (Unit), Revenue (Million USD) (2017-2021)
Table 67. F. Hoffmann-La Roche Strategic initiatives
Table 68. Novartis Profiles
Table 69. Novartis Age-related Macular Degeneration Product Introduction
Table 70. Novartis Age-related Macular Degeneration Sales (Unit), Revenue (Million USD) (2017-2021)
Table 71. Novartis Strategic initiatives
Table 72. Regeneron Pharmaceuticals Profiles
Table 73. Regeneron Pharmaceuticals Age-related Macular Degeneration Product Introduction
Table 74. Regeneron Pharmaceuticals Age-related Macular Degeneration Sales (Unit), Revenue (Million USD) (2017-2021)
Table 75. Regeneron Pharmaceuticals Strategic initiatives
Table 76. Alcon Profiles
Table 77. Alcon Age-related Macular Degeneration Product Introduction
Table 78. Alcon Age-related Macular Degeneration Sales (Unit), Revenue (Million USD) (2017-2021)
Table 79. Alcon Strategic initiatives
Table 80. Allergan Profiles
Table 81. Allergan Age-related Macular Degeneration Product Introduction
Table 82. Allergan Age-related Macular Degeneration Sales (Unit), Revenue (Million USD) (2017-2021)
Table 83. Allergan Strategic initiatives
Table 84. Avalanche Profiles
Table 85. Avalanche Age-related Macular Degeneration Product Introduction
Table 86. Avalanche Age-related Macular Degeneration Sales (Unit), Revenue (Million USD) (2017-2021)
Table 87. Avalanche Strategic initiatives
Table 88. Bausch+Lomb Profiles
Table 89. Bausch+Lomb Age-related Macular Degeneration Product Introduction
Table 90. Bausch+Lomb Age-related Macular Degeneration Sales (Unit), Revenue (Million USD) (2017-2021)
Table 91. Bausch+Lomb Strategic initiatives
Table 92. Gilead Sciences Profiles
Table 93. Gilead Sciences Age-related Macular Degeneration Product Introduction
Table 94. Gilead Sciences Age-related Macular Degeneration Sales (Unit), Revenue (Million USD) (2017-2021)
Table 95. Gilead Sciences Strategic initiatives
Table 97. Iconic Therapeutics Profiles
Table 98. Iconic Therapeutics Age-related Macular Degeneration Product Introduction
Table 99. Iconic Therapeutics Age-related Macular Degeneration Sales (Unit), Revenue (Million USD) (2017-2021)
Table 100. Iconic Therapeutics Strategic initiatives
Table 101. Neurotech Pharmaceuticals Profiles
Table 102. Neurotech Pharmaceuticals Age-related Macular Degeneration Product Introduction
Table 103. Neurotech Pharmaceuticals Age-related Macular Degeneration Sales (Unit), Revenue (Million USD) (2017-2021)
Table 104. Neurotech Pharmaceuticals Strategic initiatives
Table 105. Ohr Pharmaceutical Profiles
Table 106. Ohr Pharmaceutical Age-related Macular Degeneration Product Introduction
Table 107. Ohr Pharmaceutical Age-related Macular Degeneration Sales (Unit), Revenue (Million USD) (2017-2021)

Select User License

$2700 Single Licence
$4500 Enterprise Licence
$5900 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries